Sign Up to like & get
recommendations!
0
Published in 2020 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s235934
Abstract: Introduction Larotrectinib (VITRAKVI) is an orally potent tropomyosin receptor kinase (Trk) inhibitor that acts by competitive inhibition of all corresponding receptor kinases. It demonstrated a marked response rate (75%) and robust anticancer activity in Trk…
read more here.
Keywords:
metabolic stability;
larotrectinib using;
assessment larotrectinib;
stability ... See more keywords